Kura Oncology Stock Performance
| KURA Stock | USD 18.75 0.02 0.11% |
Kura Oncology has a performance score of 2 on a scale of 0 to 100. The company secures a Beta (Market Risk) of 1.76, which conveys a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Kura Oncology will likely underperform. Kura Oncology right now secures a risk of 3.29%. Please verify Kura Oncology semi variance, and the relationship between the maximum drawdown and accumulation distribution , to decide if Kura Oncology will be following its current price movements.
Risk-Adjusted Performance
2 of 100
Weak | Strong |
Weak
Compared to the overall equity markets, risk-adjusted returns on investments in Kura Oncology are ranked lower than 2 (%) of all global equities and portfolios over the last 90 days. Despite somewhat weak basic indicators, Kura Oncology may actually be approaching a critical reversion point that can send shares even higher in May 2024. ...more
Actual Historical Performance (%)
One Day Return 0.37 | Five Day Return 6.76 | Year To Date Return 22.4 | Ten Year Return 25.33 | All Time Return 25.33 |
1 | Compugen, Iterum Therapeutics among healthcare movers | 01/30/2024 |
2 | Kura Oncology Q4 Earnings Snapshot | 02/27/2024 |
3 | Earnings call Kura Oncology reports promising trial results, financial outlook | 03/07/2024 |
4 | Disposition of 4825 shares by Dale Stephen of Kura Oncology at 21.5502 subject to Rule 16b-3 | 03/13/2024 |
5 | Kura Oncology Shares Gap Down to 21.69 - MarketBeat | 03/20/2024 |
6 | Should You Buy Kura Oncology Inc Stock on Tuesday - InvestorsObserver | 03/26/2024 |
7 | Kura Oncology Upgraded to Hold by StockNews.com - MarketBeat | 04/03/2024 |
8 | Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635 | 04/05/2024 |
9 | Kura Oncology, Inc. Shares Bought by DekaBank Deutsche Girozentrale - Defense World | 04/15/2024 |
10 | Kura Oncology Receives Breakthrough Therapy Designation for Ziftomenib in NPM1-Mutant AML | 04/22/2024 |
| Begin Period Cash Flow | 51.8 M |
Kura |
Kura Oncology Relative Risk vs. Return Landscape
If you would invest 1,798 in Kura Oncology on January 26, 2024 and sell it today you would earn a total of 77.00 from holding Kura Oncology or generate 4.28% return on investment over 90 days. Kura Oncology is currently generating 0.1201% in daily expected returns and assumes 3.2934% risk (volatility on return distribution) over the 90 days horizon. In different words, 29% of stocks are less volatile than Kura, and 98% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Kura Oncology Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Kura Oncology's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Kura Oncology, and traders can use it to determine the average amount a Kura Oncology's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0365
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | KURA | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 3.29 actual daily | 29 71% of assets are more volatile |
Expected Return
| 0.12 actual daily | 2 98% of assets have higher returns |
Risk-Adjusted Return
| 0.04 actual daily | 2 98% of assets perform better |
Based on monthly moving average Kura Oncology is performing at about 2% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Kura Oncology by adding it to a well-diversified portfolio.
Kura Oncology Fundamentals Growth
Kura Stock prices reflect investors' perceptions of the future prospects and financial health of Kura Oncology, and Kura Oncology fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Kura Stock performance.
| Return On Equity | -0.37 | ||||
| Return On Asset | -0.23 | ||||
| Current Valuation | 1.02 B | ||||
| Shares Outstanding | 76.18 M | ||||
| Price To Earning | (9.03) X | ||||
| Price To Book | 3.73 X | ||||
| EBITDA | (164.96 M) | ||||
| Net Income | (152.63 M) | ||||
| Cash And Equivalents | 450.26 M | ||||
| Cash Per Share | 6.73 X | ||||
| Total Debt | 17.2 M | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 25.73 X | ||||
| Book Value Per Share | 5.34 X | ||||
| Cash Flow From Operations | (124.82 M) | ||||
| Earnings Per Share | (2.08) X | ||||
| Market Capitalization | 1.41 B | ||||
| Total Asset | 448.94 M | ||||
| Retained Earnings | (721.44 M) | ||||
| Working Capital | 397.22 M | ||||
| Current Asset | 86.87 M | ||||
| Current Liabilities | 5.05 M | ||||
About Kura Oncology Performance
To evaluate Kura Oncology Stock as a possible investment, you need to clearly understand its upside potential, downside risk, and overall future performance outlook. You may be satisfied when Kura Oncology generates a 15% return over the last few months, but what if the market is generating 25% over the same period? In this case, it makes sense to compare Kura Stock's performance with different market indexes, such as the Dow or NASDAQ Composite. These indexes can act as benchmarks that will help you to understand Kura Oncology market performance in a much more refined way. The Macroaxis performance score is an integer between 0 and 100 that represents Kura's market performance from a risk-adjusted return perspective. Generally speaking, the higher the score, the better is overall performance as compared to other investors. The score is normalized against the average investing universe (the best we can interpret from the data available). Within this methodology, scores of individual equity instruments will always be inferior to the scores of portfolios of equities as portfolios typically diversify a lot of unsystematic risks away. The formula to derive the Macroaxis score bases on multiple unequally-weighted factors. For more information, refer to our portfolio performance evaluation section.
Please also refer to our technical analysis and fundamental analysis pages.| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 0.00 | 0.00 | |
| Return On Tangible Assets | (0.34) | (0.36) | |
| Return On Capital Employed | (0.40) | (0.38) | |
| Return On Assets | (0.34) | (0.36) | |
| Return On Equity | (0.38) | (0.40) |
Things to note about Kura Oncology performance evaluation
Checking the ongoing alerts about Kura Oncology for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Kura Oncology help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Kura Oncology had very high historical volatility over the last 90 days | |
| Net Loss for the year was (152.63 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Kura Oncology currently holds about 450.26 M in cash with (124.82 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 6.73. | |
| Kura Oncology has a frail financial position based on the latest SEC disclosures | |
| Over 98.0% of the company shares are owned by institutional investors | |
| Latest headline from finance.yahoo.com: Kura Oncology Receives Breakthrough Therapy Designation for Ziftomenib in NPM1-Mutant AML |
- Analyzing Kura Oncology's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Kura Oncology's stock is overvalued or undervalued compared to its peers.
- Examining Kura Oncology's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Kura Oncology's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Kura Oncology's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Kura Oncology's stock. These opinions can provide insight into Kura Oncology's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Kura Oncology. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area. For information on how to trade Kura Stock refer to our How to Trade Kura Stock guide.You can also try the Aroon Oscillator module to analyze current equity momentum using Aroon Oscillator and other momentum ratios.
Complementary Tools for Kura Stock analysis
When running Kura Oncology's price analysis, check to measure Kura Oncology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kura Oncology is operating at the current time. Most of Kura Oncology's value examination focuses on studying past and present price action to predict the probability of Kura Oncology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Kura Oncology's price. Additionally, you may evaluate how the addition of Kura Oncology to your portfolios can decrease your overall portfolio volatility.
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges |
Is Kura Oncology's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Kura Oncology. If investors know Kura will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Kura Oncology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.08) | Return On Assets (0.23) | Return On Equity (0.37) |
The market value of Kura Oncology is measured differently than its book value, which is the value of Kura that is recorded on the company's balance sheet. Investors also form their own opinion of Kura Oncology's value that differs from its market value or its book value, called intrinsic value, which is Kura Oncology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Kura Oncology's market value can be influenced by many factors that don't directly affect Kura Oncology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Kura Oncology's value and its price as these two are different measures arrived at by different means. Investors typically determine if Kura Oncology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Kura Oncology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.